207 related articles for article (PubMed ID: 33355966)
1. Relationship between clinical outcomes measures and personal and social performance functioning in a prospective, interventional study in schizophrenia.
Vauth R; Carpiniello B; Turczyński J; Ivanov M; Cherubin P; Lahaye M; Schreiner A
Int J Methods Psychiatr Res; 2021 Jun; 30(2):e1855. PubMed ID: 33355966
[TBL] [Abstract][Full Text] [Related]
2. Association between symptom control and functional improvement in patients with acute schizophrenia: A post hoc analysis of an open-label, single-arm, multi-center study of paliperidone-extended release formulation.
Si TM; Zhang YL; Feng Y; Zhuo JM; Cai S; Zhang L
Psychiatry Res; 2019 Apr; 274():301-305. PubMed ID: 30831454
[TBL] [Abstract][Full Text] [Related]
3. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.
Patrick DL; Burns T; Morosini P; Rothman M; Gagnon DD; Wild D; Adriaenssen I
Curr Med Res Opin; 2009 Feb; 25(2):325-38. PubMed ID: 19192977
[TBL] [Abstract][Full Text] [Related]
4. Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia.
Li X; Ye C; Zhang W; Jia M; Wang G
CNS Drugs; 2024 Jan; 38(1):55-65. PubMed ID: 38190077
[TBL] [Abstract][Full Text] [Related]
5. Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.
Si TM; Cai SL; Zhuo JM; Zhang LL
Medicine (Baltimore); 2019 Jan; 98(3):e13688. PubMed ID: 30653088
[TBL] [Abstract][Full Text] [Related]
6. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
[TBL] [Abstract][Full Text] [Related]
7. Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
Schreiner A; Hargarter L; Hitschfield K; Lee JI; Lenskaya I; Sulaiman AH; Diels J;
Curr Med Res Opin; 2014 Jul; 30(7):1279-89. PubMed ID: 24597755
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
Petrić D; Rački V; Gačo N; Kaštelan A; Graovac M
J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):197-204. PubMed ID: 30758986
[TBL] [Abstract][Full Text] [Related]
9. Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study.
Üçok A; Saka MC; Bilici M
Nord J Psychiatry; 2015 Aug; 69(6):426-32. PubMed ID: 25549697
[TBL] [Abstract][Full Text] [Related]
10. Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.
Huang MW; Yang TT; Ten PR; Su PW; Wu BJ; Chan CH; Lan TH; Liu IC; Chiu WC; Li CY; Cheng KS; Yeh YC
BMC Clin Pharmacol; 2012 Jan; 12():1. PubMed ID: 22225965
[TBL] [Abstract][Full Text] [Related]
11. Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia.
Jelastopulu E; Giourou E; Merekoulias G; Mestousi A; Moratis E; Alexopoulos EC
BMC Psychiatry; 2014 Jul; 14():197. PubMed ID: 25005616
[TBL] [Abstract][Full Text] [Related]
12. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
13. A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
Schreiner A; Bergmans P; Cherubin P; Keim S; Rancans E; Bez Y; Parellada E; Carpiniello B; Vidailhet P; Hargarter L
Clin Ther; 2014 Oct; 36(10):1372-88.e1. PubMed ID: 25444566
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach.
Mauri M; Mauri MC; Adami M; Reggiardo G; Giulio C
Int Clin Psychopharmacol; 2015 Nov; 30(6):329-37. PubMed ID: 26230269
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of patients with schizophrenia switching from oral antipsychotics to once-monthly paliperidone palmitate (PP1M): a systematic review.
Li Q; Li X; Ye C; Jia M; Si T
BMC Psychiatry; 2024 Jan; 24(1):57. PubMed ID: 38243208
[TBL] [Abstract][Full Text] [Related]
16. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia.
Hargarter L; Bergmans P; Cherubin P; Keim S; Conca A; Serrano-Blanco A; Bitter I; Bilanakis N; Schreiner A
Expert Opin Pharmacother; 2016 Jun; 17(8):1043-53. PubMed ID: 27042990
[TBL] [Abstract][Full Text] [Related]
17. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
Canuso CM; Turkoz I; Sheehan JJ; Bossie CA
J Affect Disord; 2010 Jan; 120(1-3):193-9. PubMed ID: 19552963
[TBL] [Abstract][Full Text] [Related]
19. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
20. Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia.
Nafees B; van Hanswijck de Jonge P; Stull D; Pascoe K; Price M; Clarke A; Turkington D
Schizophr Res; 2012 Sep; 140(1-3):71-6. PubMed ID: 22749622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
